Advertisement
Canada markets open in 1 hour 19 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7264
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    82.14
    -0.59 (-0.71%)
     

  • Bitcoin CAD

    89,396.21
    +3,479.59 (+4.05%)
     

  • CMC Crypto 200

    1,337.20
    +24.58 (+1.91%)
     

  • GOLD FUTURES

    2,390.40
    -7.60 (-0.32%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,492.50
    -54.75 (-0.31%)
     

  • VOLATILITY

    18.81
    +0.81 (+4.50%)
     

  • FTSE

    7,837.40
    -39.65 (-0.50%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6816
    -0.0005 (-0.07%)
     

Endo’s Generic and International Segments Declined in Q1 2018

Kenneth Smith
Updated
Endo’s Generic and International Segments Declined in Q1 2018

Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.

Continue reading